SG49743A1 - Induction of anti-tumor cytotoxic T lymphocytes in humans using synthetic peptide epitopes - Google Patents

Induction of anti-tumor cytotoxic T lymphocytes in humans using synthetic peptide epitopes

Info

Publication number
SG49743A1
SG49743A1 SG1996004634A SG1996004634A SG49743A1 SG 49743 A1 SG49743 A1 SG 49743A1 SG 1996004634 A SG1996004634 A SG 1996004634A SG 1996004634 A SG1996004634 A SG 1996004634A SG 49743 A1 SG49743 A1 SG 49743A1
Authority
SG
Singapore
Prior art keywords
lymphocytes
humans
induction
synthetic peptide
peptide epitopes
Prior art date
Application number
SG1996004634A
Other languages
English (en)
Inventor
Ralph T Kubo
Howard M Grey
Alessandro Sette
Esteban Celis
Original Assignee
Cytel Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22684274&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG49743(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cytel Corp filed Critical Cytel Corp
Publication of SG49743A1 publication Critical patent/SG49743A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG1996004634A 1994-01-25 1995-01-25 Induction of anti-tumor cytotoxic T lymphocytes in humans using synthetic peptide epitopes SG49743A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/186,266 US5662907A (en) 1992-08-07 1994-01-25 Induction of anti-tumor cytotoxic T lymphocytes in humans using synthetic peptide epitopes

Publications (1)

Publication Number Publication Date
SG49743A1 true SG49743A1 (en) 1998-06-15

Family

ID=22684274

Family Applications (1)

Application Number Title Priority Date Filing Date
SG1996004634A SG49743A1 (en) 1994-01-25 1995-01-25 Induction of anti-tumor cytotoxic T lymphocytes in humans using synthetic peptide epitopes

Country Status (8)

Country Link
US (1) US5662907A (fr)
EP (1) EP0749315A4 (fr)
AU (1) AU1834095A (fr)
CA (1) CA2181920A1 (fr)
MX (1) MX9603007A (fr)
NZ (1) NZ281409A (fr)
SG (1) SG49743A1 (fr)
WO (1) WO1995019783A1 (fr)

Families Citing this family (113)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6419931B1 (en) * 1991-08-26 2002-07-16 Epimmune Inc. Compositions and methods for eliciting CTL immunity
US20030152580A1 (en) * 1994-07-21 2003-08-14 Alessandro Sette Hla binding peptides and their uses
US7611713B2 (en) * 1993-03-05 2009-11-03 Pharmexa Inc. Inducing cellular immune responses to hepatitis B virus using peptide compositions
US7252829B1 (en) * 1998-06-17 2007-08-07 Idm Pharma, Inc. HLA binding peptides and their uses
US20110097352A9 (en) * 1992-01-29 2011-04-28 Pharmexa Inc. Inducing cellular immune responses to hepatitis B virus using peptide and nucleic acid compositions
IL105554A (en) * 1992-05-05 1999-08-17 Univ Leiden Peptides of human papillomavirus for use in preparations elicit a human T cell response
US9340577B2 (en) * 1992-08-07 2016-05-17 Epimmune Inc. HLA binding motifs and peptides and their uses
US9266930B1 (en) * 1993-03-05 2016-02-23 Epimmune Inc. Inducing cellular immune responses to Plasmodium falciparum using peptide and nucleic acid compositions
US6540994B1 (en) * 1997-07-18 2003-04-01 I.D.M. Immuno-Designed Molecules Macrophages, process for preparing the same and their use as active substances of pharmaceutical compositions
US6410022B1 (en) * 1995-05-01 2002-06-25 Avant Immunotherapeutics, Inc. Modulation of cholesteryl ester transfer protein (CETP) activity
US5853719A (en) * 1996-04-30 1998-12-29 Duke University Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA
US7888100B2 (en) * 1996-10-03 2011-02-15 Memorial Sloan-Kettering Cancer Research Isolated nucleic acid molecules which encode immunogenic portions of NY-ESO-1 protein
US6465251B1 (en) * 1996-11-13 2002-10-15 Dana-Farber Cancer Institute, Inc. Method of promoting b-cell proliferation and activation with CD40 ligand and cyclosporin
US6087441A (en) * 1997-02-05 2000-07-11 Ludwig Institute For Cancer Research Structurally modified peptides that are resistant to peptidase degradation
WO1998058951A1 (fr) * 1997-06-23 1998-12-30 Ludwig Institute For Cancer Research Nonapeptides et decapeptides isoles se fixant a des molecules hla, et leur utilisation
US6548296B1 (en) 1997-07-23 2003-04-15 Roche Diagnostics Gmbh Methods for identifying human cell lines useful for endogenous gene activation, isolated human lines identified thereby, and uses thereof
US5891432A (en) * 1997-07-29 1999-04-06 The Immune Response Corporation Membrane-bound cytokine compositions comprising GM=CSF and methods of modulating an immune response using same
US5965535A (en) * 1997-09-12 1999-10-12 Ludwig Institute For Cancer Research Mage-3 peptides presented by HLA class II molecules
CA2316397A1 (fr) * 1997-12-24 1999-07-08 Corixa Corporation Composes destines a l'immunotherapie et au diagnostic du cancer du sein, et leur mode d'utilisation
US6432707B1 (en) 1997-12-24 2002-08-13 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US6410507B1 (en) 1997-12-24 2002-06-25 Corixa Corporation Compounds for immunotherapy and diagnosis of breast cancer and methods for their use
US6379951B1 (en) 1997-12-24 2002-04-30 Corixa Corporation Compounds for immunotherapy of breast cancer and methods for their use
US6080399A (en) * 1998-04-23 2000-06-27 Arch Development Corporation Vaccine adjuvants for immunotherapy of melanoma
US6534482B1 (en) * 1998-05-13 2003-03-18 Epimmune, Inc. Expression vectors for stimulating an immune response and methods of using the same
US7264965B2 (en) * 1998-06-05 2007-09-04 Alexis Biotech Limited Method for producing or enhancing a T-cell response against a target cell using a complex comprising an HLA class I molecule and an attaching means
US7521197B2 (en) * 1998-06-05 2009-04-21 Alexis Biotech Limited Method for producing cytotoxic T-cells
US20020051783A1 (en) * 1998-06-05 2002-05-02 Savage Philip Michael Method for producing or enhancing a T-cell response against a target cell using a complex comprising an HLA class I molecule and an attaching means
IL125608A0 (en) 1998-07-30 1999-03-12 Yeda Res & Dev Tumor associated antigen peptides and use of same as anti-tumor vaccines
AU766278B2 (en) * 1998-09-01 2003-10-16 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The PAGE-4, an X-linked gage-like gene expressed in normal and neoplastic prostate, testis and uterus, and uses therefor
US6468758B1 (en) 1998-09-23 2002-10-22 Corixa Corporation Compositions and methods for ovarian cancer therapy and diagnosis
US20070020327A1 (en) * 1998-11-10 2007-01-25 John Fikes Inducing cellular immune responses to prostate cancer antigens using peptide and nucleic acid compositions
CA2334958A1 (fr) * 1998-12-24 2000-07-06 New York Medical College Mimetiques peptidiques utiles pour traiter des maladies
IT1309584B1 (it) * 1999-02-26 2002-01-24 San Raffaele Centro Fond Peptidi immunogenici derivati da mage-3 presentati da mhc di classeii e loro uso.
US6190670B1 (en) * 1999-04-12 2001-02-20 Immtech International Inc. Use of mCRP to enhance immune responses
IT1312568B1 (it) * 1999-05-21 2002-04-22 Genera Spa Peptidi immunogenici e loro uso.
AU5045900A (en) * 1999-05-25 2000-12-12 Beth Israel Deaconess Medical Center Meth1 and meth2 polynucleotides and polypeptides
DE19925235A1 (de) 1999-06-01 2000-12-07 Medigene Ag Zytotoxische T-Zellepitope des Papillomavirus L1-Proteins und ihre Verwendung in Diagnostik und Therapie
DE19925199A1 (de) * 1999-06-01 2000-12-07 Medigene Ag Zytotoxische T-Zellepitope des Papillomavirus L1-Proteins und ihre Verwendung in Diagnostik und Therapie
CA2377525A1 (fr) * 1999-07-19 2001-03-29 Epimmune, Inc. Induction de reponses immunitaires cellulaires au virus de l'hepatite c mettant en oeuvre des compositions de peptides et d'acide nucleique
WO2001023577A2 (fr) * 1999-09-30 2001-04-05 Institut Pasteur Polynucleotides hybrides ou chimeriques, proteines et compositions comprenant des sequences du virus de l'hepatite b
US6897288B1 (en) * 1999-10-19 2005-05-24 Ludwig Institute For Cancer Research Mage-A12 antigenic peptides and uses thereof
ATE445643T1 (de) * 1999-11-18 2009-10-15 Pharmexa Inc Heteroklitische analoga von klasse-i epitopen
WO2001040269A2 (fr) 1999-11-30 2001-06-07 Corixa Corporation Compositions et methodes destinees au traitement et au diagnostic du cancer du sein
JP2003517310A (ja) * 1999-12-10 2003-05-27 エピミューン, インコーポレイテッド ペプチドおよび核酸組成物を使用する、mage2/3に対する細胞性免疫応答の誘導
US7026443B1 (en) * 1999-12-10 2006-04-11 Epimmune Inc. Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions
CA2393662A1 (fr) * 1999-12-10 2001-06-14 Epimmune Inc. Declenchement de reponses immunitaires cellulaires contre p53 au moyen de compositions d'acides nucleiques et de peptides
US20070098776A1 (en) * 1999-12-13 2007-05-03 Fikes John D HLA class I A2 tumor associated antigen peptides and vaccine compositions
CA2394741A1 (fr) * 1999-12-21 2001-06-28 Epimmune Inc. Induction de reponses immunitaires cellulaires aux antigenes du cancer de la prostate au moyen de compositions de peptides et d'acides nucleiques
US20040248113A1 (en) * 1999-12-28 2004-12-09 Alessandro Sette Method and system for optimizing multi-epitope nucleic acid constructs and peptides encoded thereby
US7462354B2 (en) * 1999-12-28 2008-12-09 Pharmexa Inc. Method and system for optimizing minigenes and peptides encoded thereby
EP1118860A1 (fr) * 2000-01-21 2001-07-25 Rijksuniversiteit te Leiden Méthodes pour sélectionner et produire des épitopes peptidiques de cellules T ainsi que des vaccines comprenant lesdits épitopes sélectionnés
ATE513913T1 (de) * 2000-05-10 2011-07-15 Sanofi Pasteur Ltd Durch mage minigene kodierte immunogene polypeptide und ihre verwendungen
CN1454082A (zh) * 2000-09-08 2003-11-05 艾普免疫公司 使用肽和核酸组合物诱导针对乙型肝炎病毒的细胞免疫应答
WO2002042325A2 (fr) 2000-10-31 2002-05-30 Zycos Inc. Acide nucleique de cyp1b1 et ses procedes d'utilisation
US20040121946A9 (en) * 2000-12-11 2004-06-24 John Fikes Inducing cellular immune responses to her2/neu using peptide and nucleic acid compositions
CA2430896A1 (fr) * 2000-12-13 2002-06-20 Argonex Pharmaceuticals, Inc. Peptides associes a la classe i du complexe majeur d'histocompatibilite et utiles dans la prevention et le traitement de la tuberculose
PL206976B1 (pl) * 2001-02-20 2010-10-29 Ortho Mcneil Pharm Inc Sposoby wytwarzania zawiesiny CD8⁺ do stosowania w leczeniu podmiotu z rakiem lub czerniakiem, sposób produkcji nie występującej naturalnie komórki i nie występująca naturalnie linia komórkowa
US20040071671A1 (en) * 2001-02-20 2004-04-15 Leturcq Didier J. Cell therapy method for the treatment of tumors
WO2002080848A2 (fr) 2001-04-09 2002-10-17 Mayo Foundation For Medical Education And Research Procedes et matieres pour traiter le cancer
WO2002092120A1 (fr) * 2001-05-15 2002-11-21 Ludwig Institute For Cancer Research Peptides structurellement modifies et leurs utilisations
US7842480B2 (en) * 2001-05-18 2010-11-30 Mayo Foundation For Medical Education And Research Chimeric antigen-specific t cell-activating polypeptides
US20060222656A1 (en) * 2005-04-01 2006-10-05 University Of Maryland, Baltimore MAGE-A3/HPV 16 peptide vaccines for head and neck cancer
WO2002097044A2 (fr) * 2001-05-25 2002-12-05 Thomas Jefferson University Formes d'epissage alternatives de proteines servant de base pour modalites therapeutiques multiples
US20030049253A1 (en) * 2001-08-08 2003-03-13 Li Frank Q. Polymeric conjugates for delivery of MHC-recognized epitopes via peptide vaccines
IL145926A0 (en) 2001-10-15 2002-07-25 Mor Research Applic Ltd Peptide epitopes of mimotopes useful in immunomodulation
WO2003105665A2 (fr) * 2002-06-14 2003-12-24 Mayo Foundation For Medical Education And Research Immunisation specifique par le virus epstein-barr
AU2003275127A1 (en) 2002-09-19 2004-04-08 Merial Limited P. ariasi polypeptides, p. perniciosus polypeptides and methods of use
EP1572968B1 (fr) 2002-10-29 2009-04-22 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Polypeptides de lutzomyia longipalpis et methodes d'utilisation desdits polypeptides
EP1609107A4 (fr) * 2003-03-28 2006-08-30 Idm Pharma Inc Procedes d'identification de variants optimaux d'epitopes peptidiques
US20050249743A1 (en) * 2004-01-12 2005-11-10 Thierry Boon-Falleur Isolated peptides which bind to HLA-A24 molecules and uses thereof
WO2005115447A2 (fr) * 2004-05-25 2005-12-08 The Trustees Of The University Of Pennsylvania Immunotherapie anticancereuse humaine
AU2005250170A1 (en) * 2004-06-01 2005-12-15 Genimmune N.V. Peptides for inducing a CTL and/or HTL response to hepatitis C virus
JP5166025B2 (ja) * 2004-06-17 2013-03-21 マンカインド コーポレイション エピトープアナログ
DE102004049223A1 (de) * 2004-10-08 2006-04-20 Johannes-Gutenberg-Universität Mainz Zubereitung zum Impfen, Impfverfahren und Verwendung einer Impf-Zubereitung
PL1942932T3 (pl) 2005-08-08 2013-11-29 Univ Oregon Health & Science Inaktywacja patogenów nadtlenkiem wodoru do wytwarzania szczepionek
EP2397852B1 (fr) 2006-03-14 2013-12-04 Oregon Health and Science University Procédés pour détecter une infection de tuberculose à mycobactérie
US20090220534A1 (en) * 2006-03-16 2009-09-03 Leiden University Medical Center Methods for identifying t-cell epitopes associated with impaired peptide processing and applications of the identified epitopes
WO2008053573A1 (fr) 2006-10-30 2008-05-08 National University Corporation Hokkaido University Remède pour néoplasme malin
EP2125868B1 (fr) 2007-02-28 2015-06-10 The Govt. Of U.S.A. As Represented By The Secretary Of The Department Of Health And Human Services Polypeptides brachyury et procédés d'utilisation
US20090117123A1 (en) * 2007-11-02 2009-05-07 National Health Research Institutes Immunopeptides of hpv e6 and e7 proteins
AU2009232774B2 (en) 2008-03-31 2014-05-29 Tella Inc. Partial peptide of Survivin presented on MHC class II molecule and use thereof
WO2010086294A2 (fr) 2009-01-28 2010-08-05 Epimmune Inc. Polypeptides de liaison de pan-dr et leurs utilisations
JP2012516350A (ja) * 2009-01-28 2012-07-19 アンティジェン・エクスプレス・インコーポレーテッド インフルエンザに対する免疫応答を調節するIi−Keyハイブリッドペプチド
WO2010099472A2 (fr) 2009-02-27 2010-09-02 The U.S.A. Of America, As Represented By The Secretary, Department Of Health And Human Services Polypeptides spanx-b et leur utilisation
AU2010305273B2 (en) 2009-10-07 2016-09-29 Uvic Industry Partnerships Inc. Vaccines comprising heat-sensitive transgenes
EP3360566B1 (fr) 2009-11-20 2019-12-25 Oregon Health&Science University Procedes destines a detecter une infection par mycrobacterium tuberculosis
WO2011112599A2 (fr) 2010-03-12 2011-09-15 The United States Of America, As Represented By The Secretary. Department Of Health & Human Services Peptides pote immunogènes et leurs procédés d'utilisation
AU2011302360B2 (en) 2010-09-14 2015-01-29 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Computationally optimized broadly reactive antigens for influenza
US9150644B2 (en) 2011-04-12 2015-10-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies that bind insulin-like growth factor (IGF) I and II
KR20140047069A (ko) 2011-06-20 2014-04-21 유니버시티 오브 피츠버그 - 오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 계산에 최적화된 광범위 반응을 나타내는 h1n1 인플루엔자를 위한 항원
CN107266558A (zh) 2011-09-06 2017-10-20 诺沃—诺迪斯克有限公司 Glp‑1衍生物
EP3766896A1 (fr) 2011-09-15 2021-01-20 The United States of America, as represented by The Secretary, Department of Health and Human Services Récepteurs des lymphocytes t reconnaissant un gène mage restreint par hla-a1 ou hla-cw7
SG11201404653UA (en) 2012-02-07 2014-09-26 Univ Pittsburgh Computationally optimized broadly reactive antigens for h3n2, h2n2, and b influenza viruses
EP2814837B1 (fr) 2012-02-13 2017-11-29 University of Pittsburgh - Of the Commonwealth System of Higher Education Antigènes largement réactifs optimisés par ordinateur pour la grippe h5n1 humaine et aviaire
ES2752190T3 (es) 2012-09-14 2020-04-03 Us Health Proteína Brachyury, vectores adenovirales que codifican proteína Brachyury y su uso
AU2014361788B2 (en) 2013-12-13 2019-10-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Multi-epitope TARP peptide vaccine and uses thereof
KR101804343B1 (ko) 2014-02-26 2017-12-04 텔라 가부시키가이샤 Wt1 항원성 폴리펩티드 및 상기 폴리펩티드를 포함하는 항종양제
US10117922B2 (en) 2014-05-13 2018-11-06 Emergex Vaccines Holding Ltd. Dengue virus specific multiple HLA binding T cell epitopes for the use of universal vaccine development
EP3177320B1 (fr) 2014-07-31 2021-01-06 The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services Anticorps monoclonaux humains dirigés contre l'epha4 et leur utilisation
CN108289940B (zh) 2015-08-03 2023-01-13 美国卫生和人力服务部 Brachyury缺失突变体、编码brachyury缺失突变体的非酵母载体及其用途
CN105037559B (zh) * 2015-08-17 2018-09-25 北京康爱瑞浩生物科技股份有限公司 治疗或预防乙肝的细胞毒性t淋巴细胞及其制备方法
CN109069575A (zh) * 2016-02-23 2018-12-21 毛里齐奥·扎内蒂 通用癌症疫苗
US11141475B2 (en) 2016-05-10 2021-10-12 Najit Technologies, Inc. Inactivating pathogens and producing highly immunogenic inactivated vaccines using a dual oxidation process
US20180161433A1 (en) * 2017-03-22 2018-06-14 Timothy Andrew Erickson Size tunable microbial mimetics for immunotherapy of thyroid carcinomas and solid tumors
BR112019023477A2 (pt) 2017-05-08 2020-06-30 Gritstone Oncology, Inc. vetores de neoantígeno de alfavírus
WO2019133853A1 (fr) * 2017-12-28 2019-07-04 Gritstone Oncology, Inc. Protéines se liant à l'antigène ciblant des antigènes partagés
KR20200118029A (ko) 2018-01-04 2020-10-14 아이코닉 테라퓨틱스, 인코포레이티드 항-조직 인자 항체, 항체-약물 결합체, 및 관련 방법
US11344614B2 (en) 2018-09-29 2022-05-31 Emergex Vaccines Holding Ltd. Pharmaceutical compositions comprising dengue virus-specific multiple HLA-binding T cell epitopes
MX2021014525A (es) 2019-05-30 2022-03-17 Gritstone Bio Inc Adenovirus modificados.
AU2020284136A1 (en) 2019-05-30 2022-01-20 Oregon Health & Science University Methods for detecting a mycobacterium tuberculosis infection
AU2020351168A1 (en) 2019-09-18 2022-04-14 Children's Medical Center Corporation An anaplastic lymphoma kinase (ALK) cancer vaccine and methods of use
KR20230046313A (ko) 2020-08-06 2023-04-05 그릿스톤 바이오, 인코포레이티드 다중에피토프 백신 카세트
FR3119325B1 (fr) 2021-01-29 2023-08-11 Renault Jean Yves Compositions liposomales orales

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5200320A (en) * 1987-12-07 1993-04-06 National Jewish Center For Immunology And Respiratory Medicine Method for identifying useful polypeptide vaccines
CA2006700A1 (fr) * 1989-01-17 1990-07-17 Antonello Pessi Peptides synthetiques et leur utilisation comme porteurs universels pour la preparation de conjugats immunogenes convenant a la mise au point de vaccins synthetiques
US5342774A (en) * 1991-05-23 1994-08-30 Ludwig Institute For Cancer Research Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
AU4998993A (en) * 1992-08-07 1994-03-03 Epimmune, Inc. Hla binding peptides and their uses
US5405940A (en) * 1992-08-31 1995-04-11 Ludwig Institute For Cancer Research Isolated nonapeptides derived from MAGE genes and uses thereof
ES2225824T3 (es) * 1992-08-31 2005-03-16 Ludwig Institute For Cancer Research Nonapeptido aislado derivado del gen mage-3 y presentado por hla-a1, y sus usos.
WO1995004817A1 (fr) * 1993-08-06 1995-02-16 Cytel Corporation Procedes de therapie ex-vivo recourant a des cellules presentatrice d'antigenes porteurs de peptides pour activer des ctl
AU2361595A (en) * 1994-04-22 1995-11-16 Sloan-Kettering Institute For Cancer Research Induction of cytotoxic t lymphocytes (ctl) using antigenic peptides and a suitable adjuvant

Also Published As

Publication number Publication date
MX9603007A (es) 1998-05-31
US5662907A (en) 1997-09-02
NZ281409A (en) 2000-01-28
WO1995019783A1 (fr) 1995-07-27
CA2181920A1 (fr) 1995-07-27
EP0749315A4 (fr) 2000-01-05
AU1834095A (en) 1995-08-08
EP0749315A1 (fr) 1996-12-27

Similar Documents

Publication Publication Date Title
SG49743A1 (en) Induction of anti-tumor cytotoxic T lymphocytes in humans using synthetic peptide epitopes
PL320612A1 (en) Induction of response of t cytotoxic lymphocytes
GB9206757D0 (en) Novel peptide receptor ligands
GB9221654D0 (en) Recombinant human anti-cytomegalovirus antibodies
HUP9801746A3 (en) Lymphotoxin-alfa/beta complexes and anti-lymphotoxin-beta receptor antibodies as anti-tumor agents
GB9201284D0 (en) Seats
IL116658A0 (en) Peptides their preparation and use
HU9301768D0 (en) Linear peptides
EP0935608A4 (fr) Peptides cytotoxiques
GB2269987B (en) Seat
GB9200021D0 (en) Seating
GB2301620B (en) Seats
GB9010740D0 (en) Peptide compounds and their preparation
GB2271278B (en) Concept in seating
GB9201032D0 (en) Composite seat
GB9203027D0 (en) Particulate composite material
GB9213660D0 (en) Seat belt cover
AU116725S (en) Seat belt cover
GB9200055D0 (en) Modified seat belt
GB9216225D0 (en) Seat belt
GB2270467B (en) Seating
GB9508569D0 (en) Particulate composite material
GB2266658B (en) Seat
GB2247164B (en) Trolley seat
GB9008361D0 (en) Modified peptide